News

Analysis of the American Rheumatology Network-Trio Health (ARN-Trio) registry finds that AbbVie’s Rinvoq use is increasing rapidly as a proportion of JAK inhibitor use. Rheumatologists are asking, why is use of AbbVie’s Rinvoq increasing so rapidly? Given the higher cost of Rinvoq (annual net price $44,035) and similar safety and efficacy across the JAK inhibitor …

Formulary Exclusions Favor Rinvoq Use and Increase Costs Read More »

American Rheumatology Network (ARN) and Trio Health (Trio) have launched the first rheumatology registry that combines pharmacy dispensing data with electronic medical records (EMR) to provide unparalleled real-world insights into patient experiences and outcomes. The new database includes over 75,000 patients within the ARN’s national network, serving as a comprehensive data solution that combines EMR, …

Join the ARN-Trio Health Registry, Inform Your Clinical Care and Generate Additional Revenue Read More »

The American Rheumatology Network (ARN) has been so successful with cost management, particularly via the use of biosimilars, that it believes its model is worthy of emulation, said Colin C. Edgerton, MD, executive chairman of ARN, who spoke on the subject recently in an Academy of Managed Care Pharmacy–sponsored webinar. “Certainly, rheumatologists are eager to …

ARN Physician Featured in: American Rheumatology Network Promotes a Biosimilar Pathway Read More »

by Colin Edgerton We are seeing COVID-19 cases peak in many areas of the US, prompting thoughts about what comes next for rheumatology practices. Many community rheumatology practices have been hit hard by the crisis, and we hope that sharing “lessons learned” will inform practices on what steps to take now, and what to anticipate …

Weathering the Storm: A Successful Rheumatology Practice During the COVID Crisis Read More »

As of 12:30pm ET on March 17, 2020 CMS has sent out an official notification stating that effective for services starting March 6, 2020 (retroactive), the limitations on where Medicare patients are eligible for telehealth services has been removed during the emergency. The waiver temporarily eliminates the requirement that the originating site must be a …

American Rheumatology Network Telehealth Payer Update: COVID-19 Read More »

The American Rheumatology Network (ARN) continues to monitor federal, state and local health advisories regarding the coronavirus (COVID-19) and will update this resource accordingly.  Please note this document contains general information which may not be applicable to all patients, facilities, communities and circumstances. This resource guide is intended to provide you with suggestions on how …

A Resource for Independent Rheumatology Clinics: COVID-19 Read More »

Updated March 17, 2020 3:00pm American Rheumatology Network (ARN) members are concerned about safe access to care during the COVID-19 pandemic. The Centers for Disease Control and Prevention (CDC) has recommended use of telehealth, when clinically appropriate, to lessen the risk of disease transmission. CDC recommendations are fluid and rapidly changing, and rheumatologists and rheumatology …

American Rheumatology Telehealth Overview: Caring for Patients during the COVID-19 Pandemic Read More »

Originally published in The Rheumatologist The Centers for Medicare & Medicaid Services (CMS) Physician Fee Schedule final rule for 2020 includes a big win for rheumatologists—a 15% increase in reimbursement for evaluation and management (E/M) services. This decision represents an historic hike in payment for these codes and resulted from 10 years of advocacy work …

ARN Physician Featured: 15% E/M Services Reimbursement Hike a Win for Rheumatology Read More »

Charleston, SC, Feb. 18, 2020 – American Rheumatology Network (ARN) announces their partnership with Framework Management Information, Inc. (Framework) to develop AXCESS1, a new prescription access hub. AXCESS1 seamlessly interfaces with healthcare practices, specialty pharmacies, and pharmaceutical manufacturers serving as a “one-stop shop” for information pertaining to prior authorization status, patient assistance programs, and medication …

American Rheumatology Network and Framework Partner to Develop New Prescription Access Hub, AXCESS1 Read More »

Originally published in Biosimilar Development In the first installment of this four-part series, the members of the Biosimilar Development Editorial Board and friends discussed how 2019 turned out for the biosimilar industry. But as we face 2020, several big questions remain from the past year and about what the future may (or may not) bring …

ARN Physician Featured: What Does 2020 Hold for Biosimilars? Industry Experts Weigh In Read More »